EuroPCR 2023 | New Renal Denervation Devices Show Promising Results

The Netrod System study included 205 patients with uncontrolled essential hypertension while taking two drugs (nifedipine and hydrochlorothiazide), who were randomized 2:1 to denervation or sham control. All subjects had undergone renal angiography before randomization.

Renal denervation was done using the Setrod System device.

Mean patient age was 50 years old, and 16% of subjects were female.

In-office blood pressure was about 161/100 mmHg, and 152/96 mmHg during the 24-hour outpatient monitoring.

Those who underwent renal denervation more frequently reached the target blood pressure, 140/90 mmHg (64.7% vs. 7.7%; p = <0.0001), and a reduction of at least 5 mmHg in systolic blood pressure in the office setting (93.4% vs. 60%; p ≤ 0.0001).

Denervation-related complications were few. Only one patient presented a renal artery dissection, but it was related to catheterization.

Read also: EuroPCR 2023 | More Evidence in Favor of Renal Denervation.

Authors conclude that denervation with the Netrod System is safe and effective in patients with essential hypertension.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Reference: The Netrod System, presentado por el Dr. Fei Gao en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...